KAPA
Kairos Pharma, Ltd.KAPA
KAPA
About: Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.35% more ownership
Funds ownership: 0% [Q2] → 0.35% (+0.35%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
473%
upside
Avg. target
$9
473%
upside
High target
$9
473%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 473%upside $9 | Buy Maintained | 14 Nov 2024 |
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 473%upside $9 | Buy Initiated | 14 Oct 2024 |
Financial journalist opinion
Based on 3 articles about KAPA published over the past 30 days
Neutral
Accesswire
5 days ago
Kairos Pharma to Participate in The Microcap Conference in January 2025
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
Neutral
Business Wire
2 weeks ago
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients. City of Hope Cancer Center is the first of several planned new centers to be added in the coming weeks to support the Company.
Neutral
GlobeNewsWire
3 weeks ago
IBN Initiates Coverage of Kairos Pharma Ltd.
LOS ANGELES, Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on advancing innovative oncology therapeutics, has selected IBN, a multifaceted financial news and publishing company for private and public entities, to spearhead its corporate communications efforts.
Neutral
GlobeNewsWire
1 month ago
Kairos Pharma to Present at the LD Micro Main Event XVII
LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Neutral
GlobeNewsWire
2 months ago
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit where he will be speaking with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.
Neutral
GlobeNewsWire
2 months ago
Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA-certified and CAP-accredited clinical laboratory specializing in genetic sequencing. The partnership focuses on the development of companion biomarkers for Kairos Pharma's cancer therapy, ENV105, which targets prostate and lung cancers. This strategic agreement aims to advance the precision of patient screening and therapy monitoring for Kairos Pharma's Phase 1 and Phase 2 clinical trials, with the aim of advancing cancer treatment by identifying patients who will benefit most from ENV105.
Positive
Seeking Alpha
3 months ago
U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost
Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition, respectively. Seven IPOs and three SPACs submitted initial filings. Eight companies are expected to price their IPOs in the upcoming week, including three larger deals.
Neutral
GlobeNewsWire
3 months ago
Kairos Pharma Closing of $6.2 Million Initial Public Offering
LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”) (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces that it has closed its initial public offering of 1,550,000 shares of common stock at an offering price of $4.00 per share. The gross proceeds to the Company from the offering were $6,200,000, before deducting underwriting discounts and commissions and other offering expenses. The Company's common stock began trading on the NYSE American LLC on September 16, 2024 under the symbol “KAPA.”
Neutral
GlobeNewsWire
3 months ago
Kairos Pharma Prices $6.2 Million Initial Public Offering
Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA” Company anticipates commencement of trading on the NYSE American effective September 16, 2024 under the symbol “KAPA”
Positive
Market Watch
10 months ago
Kairos Pharma to sell 1.55 million shares in IPO at $4 each
Kairos Pharma plans to sell about 1.55 million shares in its initial public offering at $4 per share.
Charts implemented using Lightweight Charts™